| Name | mitogen-activated protein kinase kinase kinase 21 |
| Description | Predicted to enable JUN kinase kinase kinase activity and protein homodimerization activity. Predicted to be involved in protein autophosphorylation and signal transduction. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Mar 2025] |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n MAP3K21, also known as MLK4, is a mixed‐lineage kinase that orchestrates diverse signaling cascades with context‐dependent effects on cell fate, tumor progression, immune responses, and even metabolic regulation. In glioblastoma stem cells, MLK4 is overexpressed in the mesenchymal subtype and drives NF‑κB signaling via phosphorylation of IKKα, thereby promoting self‑renewal, motility, tumorigenesis, and radioresistance."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " In macrophages, MLK4 interacts with Toll‑like receptor 4 to inhibit LPS‑induced activation of MAP kinases and TNF‑α production, functioning as a negative regulator of inflammatory signaling."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In the context of colorectal cancer, MLK4 appears to play a dual role. On one hand, constitutively active MLK4 alleles enhance transformation and tumorigenicity through activation of the MEK/ERK pathway"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": ", while on the other hand, loss of MLK4 expression is associated with poorer overall and progression‑free survival, particularly in KRAS‑mutated tumors."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In breast cancer—especially in the triple‑negative subtype—MLK4 is frequently upregulated. High MLK4 expression drives NF‑κB activation, promotes a mesenchymal phenotype, and enhances proliferation and invasiveness"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": ", while its role in regulating the DNA damage response contributes to chemoresistance."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In hepatocellular carcinoma, overexpression of MLK4 correlates with aggressive tumor growth and metastasis via increased reactive oxygen species production and subsequent activation of p38, JNK, and ERK pathways."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": " In gastric carcinoma cells, reconstitution of MLK4 function has been shown to inhibit cell viability, migration, and invasion."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Moreover, in pancreatic cancer cells, MLK4 is recruited by the IL‑17 receptor IL‑17RB, where it phosphorylates the receptor to trigger subsequent ubiquitination and assembly of an NF‑κB activator complex that promotes oncogenic signaling."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "9"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Beyond oncogenesis, a coding variant in MAP3K21 has been significantly associated with pediatric adiposity, suggesting that MLK4 may also play a role in metabolic regulation."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "10"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings underscore MAP3K21/MLK4 as a multifaceted regulator of NF‑κB, MAPK, and DNA damage response pathways. Its activity can promote aggressive traits—in part by enhancing mesenchymal features, survival, and chemoresistance in cancer cells—or, in other contexts, its loss correlates with adverse outcomes. This context‐dependent functionality highlights MLK4 as a promising target for therapeutic intervention across various disease states.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Sung-Hak Kim, Ravesanker Ezhilarasan, Emma Phillips, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Cell (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ccell.2016.01.005"}], "href": "https://doi.org/10.1016/j.ccell.2016.01.005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26859459"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26859459"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Alim Seit-Nebi, Wei Cheng, Hong Xu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MLK4 has negative effect on TLR4 signaling."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Mol Immunol (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/cmi.2011.15"}], "href": "https://doi.org/10.1038/cmi.2011.15"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21602844"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21602844"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Miriam Martini, Mariangela Russo, Simona Lamba, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-12-3074"}], "href": "https://doi.org/10.1158/0008-5472.CAN-12-3074"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23319808"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23319808"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Lydia Brandl, David Horst, Thomas G P Grünewald, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clinical Evidence on the Interaction Between MLK4, KRAS and Microsatellite Instability to Determine the Prognosis of Early-Stage Colorectal Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Physiol Biochem (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.33594/000000175"}], "href": "https://doi.org/10.33594/000000175"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31701729"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31701729"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Anna A Marusiak, Monika K Prelowska, Dawid Mehlich, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncogene (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41388-018-0618-0"}], "href": "https://doi.org/10.1038/s41388-018-0618-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30552384"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30552384"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Dawid Mehlich, Michał Łomiak, Aleksandra Sobiborowicz, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Death Dis (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41419-021-04405-0"}], "href": "https://doi.org/10.1038/s41419-021-04405-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34839359"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34839359"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Yu Li, Haibo Zuo, Hongjian Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Decrease of MLK4 prevents hepatocellular carcinoma (HCC) through reducing metastasis and inducing apoptosis regulated by ROS/MAPKs signaling."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biomed Pharmacother (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.biopha.2019.108749"}], "href": "https://doi.org/10.1016/j.biopha.2019.108749"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31071576"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31071576"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Yu Xi, Jianhua Niu, Dongmei Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Mixed lineage kinase-4 promotes gastric carcinoma tumorigenesis through suppression of the c-Jun N-terminal kinase signaling pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Exp Ther Med (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/etm.2018.6618"}], "href": "https://doi.org/10.3892/etm.2018.6618"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30233678"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30233678"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Heng-Hsiung Wu, Lung-Hung Tsai, Chun-Kai Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Sci Transl Med (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1126/scitranslmed.abc2823"}], "href": "https://doi.org/10.1126/scitranslmed.abc2823"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33658352"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33658352"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Ke Mao, Meixian Zhang, Jinshuai Cao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Coding Variants are Relevant to the Expression of Obesity-Related Genes for Pediatric Adiposity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Obesity (Silver Spring) (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/oby.23046"}], "href": "https://doi.org/10.1002/oby.23046"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34494379"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34494379"}]}]}]}
|
| NCBI Gene ID | 84451 |
| API | |
| Download Associations | |
| Predicted Functions |
![]() |
| Co-expressed Genes |
![]() |
| Expression in Tissues and Cell Lines |
![]() |
MAP3K21 has 1,264 functional associations with biological entities spanning 6 categories (functional term, phrase or reference, chemical, disease, phenotype or trait, cell line, cell type or tissue, gene, protein or microRNA, sequence feature) extracted from 28 datasets.
Click the + buttons to view associations for MAP3K21 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| ChEA Transcription Factor Targets 2022 | transcription factors binding the promoter of MAP3K21 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset. | |
| CM4AI KOLF21J CRISPRi Gene Perturbation Atlas | gene perturbations changing expression of MAP3K21 gene from the CM4AI KOLF21J CRISPRi Gene Perturbation Atlas dataset. | |
| COMPARTMENTS Experimental Protein Localization Evidence Scores 2025 | cellular components containing MAP3K21 protein in low- or high-throughput protein localization assays from the COMPARTMENTS Experimental Protein Localization Evidence Scores 2025 dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 | cellular components co-occuring with MAP3K21 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 dataset. | |
| DeepCoverMOA Drug Mechanisms of Action | small molecule perturbations with high or low expression of MAP3K21 protein relative to other small molecule perturbations from the DeepCoverMOA Drug Mechanisms of Action dataset. | |
| DepMap CRISPR Gene Dependency | cell lines with fitness changed by MAP3K21 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset. | |
| DISEASES Experimental Gene-Disease Association Evidence Scores 2025 | diseases associated with MAP3K21 gene in GWAS datasets from the DISEASES Experimental Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores 2025 | diseases co-occuring with MAP3K21 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| GO Biological Process Annotations 2023 | biological processes involving MAP3K21 gene from the curated GO Biological Process Annotations 2023 dataset. | |
| GO Biological Process Annotations 2025 | biological processes involving MAP3K21 gene from the curated GO Biological Process Annotations2025 dataset. | |
| GO Molecular Function Annotations 2023 | molecular functions performed by MAP3K21 gene from the curated GO Molecular Function Annotations 2023 dataset. | |
| GO Molecular Function Annotations 2025 | molecular functions performed by MAP3K21 gene from the curated GO Molecular Function Annotations 2025 dataset. | |
| GTEx eQTL 2025 | SNPs regulating expression of MAP3K21 gene from the GTEx eQTL 2025 dataset. | |
| GTEx Tissue Gene Expression Profiles 2023 | tissues with high or low expression of MAP3K21 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles 2023 dataset. | |
| GWAS Catalog SNP-Phenotype Associations 2025 | phenotypes associated with MAP3K21 gene in GWAS datasets from the GWAS Catalog SNP-Phenotype Associations 2025 dataset. | |
| JASPAR Predicted Human Transcription Factor Targets 2025 | transcription factors regulating expression of MAP3K21 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Human Transcription Factor Targets dataset. | |
| JASPAR Predicted Mouse Transcription Factor Targets 2025 | transcription factors regulating expression of MAP3K21 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Mouse Transcription Factor Targets 2025 dataset. | |
| KEGG Pathways 2026 | pathways involving MAP3K21 protein from the KEGG Pathways 2026 dataset. | |
| Kinase Library Tyrosine Kinome Atlas | kinases that phosphorylate MAP3K21 protein from the Kinase Library Tyrosine Kinome Atlas dataset. | |
| NIBR DRUG-seq U2OS MoA Box Gene Expression Profiles | drug perturbations changing expression of MAP3K21 gene from the NIBR DRUG-seq U2OS MoA Box dataset. | |
| Rummagene Transcription Factor Associations 2026 | transcription factors regulating expression of MAP3K21 gene from the Rummagene Transcription Factor Associations 2026 dataset. | |
| RummaGEO Drug Perturbation Signatures | drug perturbations changing expression of MAP3K21 gene from the RummaGEO Drug Perturbation Signatures dataset. | |
| RummaGEO Gene Perturbation Signatures | gene perturbations changing expression of MAP3K21 gene from the RummaGEO Gene Perturbation Signatures dataset. | |
| Sci-Plex Drug Perturbation Signatures | drug perturbations changing expression of MAP3K21 gene from the Sci-Plex Drug Perturbation Signatures dataset. | |
| Tahoe Therapeutics Tahoe 100M Perturbation Atlas | drug perturbations changing expression of MAP3K21 gene from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores 2025 | tissues with high expression of MAP3K21 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores 2025 dataset. | |
| TISSUES Experimental Tissue Protein Expression Evidence Scores 2025 | tissues with high expression of MAP3K21 protein in proteomics datasets from the TISSUES Experimental Tissue Protein Expression Evidence Scores 2025 dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 | tissues co-occuring with MAP3K21 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset. | |